David Amsellem
Stock Analyst at Piper Sandler
(4.79)
# 85
Out of 5,157 analysts
165
Total ratings
65.19%
Success rate
22.65%
Average return
Main Sectors:
Stocks Rated by David Amsellem
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TEVA Teva Pharmaceutical Industries | Reiterates: Overweight | $40 → $41 | $31.52 | +30.08% | 12 | Mar 4, 2026 | |
| PTHS Pelthos Therapeutics | Initiates: Overweight | $48 | $25.31 | +89.65% | 1 | Feb 27, 2026 | |
| BMY Bristol-Myers Squibb Company | Maintains: Overweight | $66 → $75 | $60.13 | +24.73% | 3 | Feb 23, 2026 | |
| AMGN Amgen | Maintains: Overweight | $381 → $432 | $375.43 | +15.07% | 7 | Feb 18, 2026 | |
| ABBV AbbVie | Maintains: Overweight | $289 → $299 | $227.01 | +31.71% | 4 | Feb 18, 2026 | |
| BIIB Biogen | Maintains: Neutral | $157 → $177 | $188.41 | -6.06% | 4 | Feb 9, 2026 | |
| VTRS Viatris | Maintains: Neutral | $9 → $12 | $14.08 | -14.77% | 8 | Jan 28, 2026 | |
| AXSM Axsome Therapeutics | Maintains: Overweight | $148 → $223 | $166.34 | +34.06% | 4 | Jan 16, 2026 | |
| FENC Fennec Pharmaceuticals | Initiates: Overweight | $18 | $7.89 | +128.14% | 1 | Jan 9, 2026 | |
| JAZZ Jazz Pharmaceuticals | Reiterates: Overweight | $147 → $219 | $185.93 | +17.79% | 15 | Dec 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $9 | $2.70 | +233.33% | 1 | Nov 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $8 | $4.20 | +90.48% | 2 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $6 → $8 | $5.82 | +37.46% | 6 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $11 → $13 | $13.35 | -2.62% | 5 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $175 → $179 | $129.86 | +37.84% | 12 | Oct 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $38 → $45 | $27.74 | +62.22% | 8 | Oct 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $40 → $65 | $53.67 | +21.11% | 17 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $30 → $25 | $18.91 | +32.21% | 9 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $131 → $121 | $33.54 | +260.76% | 8 | Aug 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $24 → $18 | $6.48 | +177.78% | 6 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $36 → $37 | $36.61 | +1.07% | 8 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $68 | $75.96 | -10.48% | 1 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $9 → $3 | $5.40 | -44.44% | 7 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 | $22.44 | +87.17% | 10 | Jul 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $21 | $3.70 | +467.57% | 3 | Feb 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $72 → $42 | $28.74 | +46.14% | 3 | Oct 16, 2023 |
Teva Pharmaceutical Industries
Mar 4, 2026
Reiterates: Overweight
Price Target: $40 → $41
Current: $31.52
Upside: +30.08%
Pelthos Therapeutics
Feb 27, 2026
Initiates: Overweight
Price Target: $48
Current: $25.31
Upside: +89.65%
Bristol-Myers Squibb Company
Feb 23, 2026
Maintains: Overweight
Price Target: $66 → $75
Current: $60.13
Upside: +24.73%
Amgen
Feb 18, 2026
Maintains: Overweight
Price Target: $381 → $432
Current: $375.43
Upside: +15.07%
AbbVie
Feb 18, 2026
Maintains: Overweight
Price Target: $289 → $299
Current: $227.01
Upside: +31.71%
Biogen
Feb 9, 2026
Maintains: Neutral
Price Target: $157 → $177
Current: $188.41
Upside: -6.06%
Viatris
Jan 28, 2026
Maintains: Neutral
Price Target: $9 → $12
Current: $14.08
Upside: -14.77%
Axsome Therapeutics
Jan 16, 2026
Maintains: Overweight
Price Target: $148 → $223
Current: $166.34
Upside: +34.06%
Fennec Pharmaceuticals
Jan 9, 2026
Initiates: Overweight
Price Target: $18
Current: $7.89
Upside: +128.14%
Jazz Pharmaceuticals
Dec 10, 2025
Reiterates: Overweight
Price Target: $147 → $219
Current: $185.93
Upside: +17.79%
Nov 25, 2025
Initiates: Overweight
Price Target: $9
Current: $2.70
Upside: +233.33%
Nov 7, 2025
Maintains: Overweight
Price Target: $5 → $8
Current: $4.20
Upside: +90.48%
Nov 7, 2025
Maintains: Neutral
Price Target: $6 → $8
Current: $5.82
Upside: +37.46%
Oct 31, 2025
Reiterates: Overweight
Price Target: $11 → $13
Current: $13.35
Upside: -2.62%
Oct 29, 2025
Maintains: Overweight
Price Target: $175 → $179
Current: $129.86
Upside: +37.84%
Oct 23, 2025
Reiterates: Overweight
Price Target: $38 → $45
Current: $27.74
Upside: +62.22%
Oct 9, 2025
Upgrades: Overweight
Price Target: $40 → $65
Current: $53.67
Upside: +21.11%
Aug 8, 2025
Maintains: Neutral
Price Target: $30 → $25
Current: $18.91
Upside: +32.21%
Aug 1, 2025
Maintains: Overweight
Price Target: $131 → $121
Current: $33.54
Upside: +260.76%
May 15, 2025
Maintains: Overweight
Price Target: $24 → $18
Current: $6.48
Upside: +177.78%
May 9, 2025
Reiterates: Neutral
Price Target: $36 → $37
Current: $36.61
Upside: +1.07%
Oct 11, 2024
Initiates: Overweight
Price Target: $68
Current: $75.96
Upside: -10.48%
Aug 2, 2024
Downgrades: Underweight
Price Target: $9 → $3
Current: $5.40
Upside: -44.44%
Jul 3, 2024
Maintains: Overweight
Price Target: $42
Current: $22.44
Upside: +87.17%
Feb 16, 2024
Maintains: Overweight
Price Target: $20 → $21
Current: $3.70
Upside: +467.57%
Oct 16, 2023
Maintains: Overweight
Price Target: $72 → $42
Current: $28.74
Upside: +46.14%